Stay updated with breaking news from Pfizer Stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sales for Pfizer’s COVID-19 vaccine and oral treatment declined nearly 70% annually during the first quarter, underscoring the company’s earnings headaches as heads turned toward weight loss drugs.
The current status of this stock might seem bleak. But like a chess grandmaster, Griffin is looking several moves ahead.
Income investors can enjoy the nearly 6% dividend yield even if growth doesn't return.
The drugmaker's Q4 results were better than many expected, but still not good enough to spark a sustained rally.
Pfizer shares have slipped in the double digits over the past year.